ABSTRACT:
Purpose: In recent years, experimental studies have shown that some angiotensin-converting enzyme (ACE) inhibitors with antihypertensive effects have anticonvulsant effects against seizures. After the seizure, the process of inflammation begins in the brain and body, with the production of free radicals. Renin has some effects on the central nervous system of the angiotensin system. The current study's objective was to examine how captopril, an ACE inhibitor, affects neuroinflammation in the hippocampus and cortical areas in acute epileptic seizures and post-seizures induced by pentylenetetrazole (PTZ).
Material and Methods: Eighteen Wistar Albino rats were separated into three groups: control, PTZ (serum physiologic 1 ml/kg as solvent), and captopril (50 mg/kg/day for 7days). To produce epileptic seizures, PTZ (45 mg/kg) was delivered thirty minutes after the drug was administered. The animals were monitored during 30 minutes to record seizures scoring scale and the onset time of first myoclonic jerk (FMJ). In the brain tissue, the activity of TNF- α, IL-1 β, NF-kB, COX-1, and COX-2 were examined.
Results: Captopril increased FMJ onset time and reduced seizure stage as compared to the PTZ group (p<0.05). Additionally, captopril treatment dramatically decreased the expression of TNF- α, IL-1 β and COX-2 in the hippocampus and cortex, while, it enhanced the level of COX-1.
Conclusion: Captopril improves epileptic seizure parameters and attenuated its effect on neuroinflammatory damage caused by PTZ. In epileptic patient’s hypertension, captopril may be effective as a supportive treatment drug.
Primary Language | English |
---|---|
Subjects | Clinical Sciences (Other) |
Journal Section | Articles |
Authors | |
Early Pub Date | October 1, 2023 |
Publication Date | September 30, 2023 |
Submission Date | July 26, 2023 |
Acceptance Date | September 6, 2023 |
Published in Issue | Year 2023 Volume: 4 Issue: 3 |
Turkish Journal of Science and Health (TFSD)
E-mail: tfsdjournal@gmail.com
Bu eser Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.